AIDP Announces a New Published Study for PureMune®, the Patented Beta-Glucan from Immudyne Nutritional

1024 373 AIDP

July 11, 2023, AIDP, Inc. (City of Industry, CA) is pleased to announce a new published pilot study on PureMune®, a patented beta-glucan from its partner Immudyne Nutritional (Jacksonville, FL).  The researchers found that 30 mg daily of PureMune consistently stimulated the production of immune cells, significantly increasing the levels of interferon-gamma (IFN-γ), interleukin-2 (IL-2) and the IFN-γ/interleukin-4 (IL-4) ratio, which together contributed to reduced incidence and duration of symptomatic episodes compared to the same winter period the year before.  The study was conducted among healthy participants who had at least four common colds over the preceding 12 months and lasted 90 days. 

Beta-glucan has been found to stimulate the immune system, promoting the activation of certain immune cells such as macrophages and neutrophils. Puremune® is a patented, fast acting, low dose form compared to other forms.  Conventional beta-glucan ingredients need anywhere from six to 12 days to produce a clinically relevant response in only one immune pathway at a dose of 250 mg or more.  PureMune, on the other hand, offers: a rapid onset of action—within three hours; supports three components of immunity—dectin-1 receptors, toll-like receptors (TLRs) and complement receptor 3 (CR3); and does all this for a lower cost of dose, as only 30 mg a day is needed to support immunity.

“Our research has shown best-in-class PureMune to be a very fast-acting and high-performing beta-glucan ingredient for immune support,” said Mark McLaughlin, chief executive officer of Immudyne Nutritional. “PureMune’s low dosage offers many benefits when developing immune health products as companies can now blend in other science-based immune ingredients such as probiotics, vitamin C or elderberry to create optimal immune formulations using different delivery systems.”

“Adding new research to the Puremune portfolio provides an added advantage for our customers and consumers,” said Mark Thurston, President of AIDP. 

When choosing a beta-glucan supplement, it is important to look for products that are standardized to contain a specific amount of beta-glucan. This ensures that you are getting a consistent and reliable dosage. Immundyne operates in a U.S. FDA-registered facility, utilizing Eurofins Scientific carbon-13 high-resolution nuclear magnetic resonance (HR-NMR) to validate PureMune’s purity, authenticity and freedom from common allergens.


About AIDP, Inc.
AIDP is a leader in functional ingredients, with a focus on extensively researched products that meet consumer demand for wellness and healthy aging. Its commitment is to source high-quality ingredients and provide proprietary solutions that address formulation challenges. AIDP’s success is grounded in its depth of experience and commitment to strong science. For more information contact us at and visit

Press Contact:
Kathy Lund
VP Marketing AIDP, Inc.